Open AccessPB1834 PRALATREXATE EXPERIENCE IN NON HODGKIN LYMPHOMA
Author(s) -
EncisoOlivera L.,
Patiño B.,
Diaz M.,
Martinez H.,
Otero D.,
Spirko P.,
Acon C.
Publication year - 2019
Publication title -
hemasphere
Language(s) - Italian
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000565840.37777.53
Subject(s) - medicine , mycosis fungoides , lymphoma , mucositis , anaplastic large cell lymphoma , t cell lymphoma , oncology , dermatology , chemotherapy , gastroenterology , surgery
Please indicate where the abstract has been published before: Third National Congress of clinical investigation. Colombian Association of Oncology and Hematology (ACHO) Background: Pralatrexate is an antimetabolite used mainly in the treatment of relapsed or refractory peripheral T‐cell lymphoma. However, due to its low prevalence rate, and a small population analyzed in the trials, there is not a trial which evaluated results in ordinarily practice in our knowledge. Aims: To study the treatment with Pralatrexate in a 10 patients series with T‐cell lymphoma, both nodal and cutaneous, attended in our institution. Methods: Case series. Patients older than 18 years old, with a diagnosis of T‐Cell lymphoma, any subtype, treated with at least one cycle of Pralatrexate with available information for following up and treatment evaluation. All the analysis were made in the statistic package R (Version 3.4.3) and STATA 15. Results: Ten patients were included, 50% were men. The median was 47.8 years (IQR 17.04). The 50% had a Mycosis Fungoides (MF) diagnostic, being the most frequent histologic type. Five patients had the diagnosis of T Cell Lymphoma NOS which, one (10%) T cell Lymphoma ALK‐negative, one (10%) angioimmunoblastic lymphoma and one (10%) primary cutaneous anaplastic lymphoma. All the patients had received a prior treatment based on anthracyclines. The number of treatment received prior to the Pralatrexate beginning was a mean of 2,8 (SD 1.03). The 30% (three patients) suffered grade 3 mucositis in at least one cycle. Four patients required to be admitted at least in a cycle due to complications related to the treatment, and a patient required to be admitted in an intensive care unit requiring vasopressor support. None opportunistic infections were reported nor febrile neutropenia related to the other treatment cycles. A patient (10%) reached out complete response, two patients were in stable disease. Six patients (60%) progressed during the treatment after a mean of 2.8 cycles (1 to 4). At the last evaluation time, five (50%) of patients had started a new treatment line. Summary/Conclusion: The pralatrexate treatment in our patients with T cell lymphoma diagnosis offers a low response and short duration rates. Despite its good tolerance, also there is a high risk of complications, mainly mucositis.